neobookRx
GuidelinesOther guideline

References - SATS Asthma

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2021. www.ginasthma.org (accessed 19 August 2021). Louw SJ, Bateman ED, Plit M, Joubert J. Guidelines for the management of asthma in adults in South Africa. Part I. Chronic persistent asthma. Statement by a working group of the South African Pulmonology Society. S Afr Med J 1992;81(6):319-322. Lalloo UG, Bateman

  1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2021. www.ginasthma.org (accessed 19 August 2021).
  2. Louw SJ, Bateman ED, Plit M, Joubert J. Guidelines for the management of asthma in adults in South Africa. Part I. Chronic persistent asthma. Statement by a working group of the South African Pulmonology Society. S Afr Med J 1992;81(6):319-322.
  3. Lalloo UG, Bateman ED, Feldman C, et al. Guideline for the management of chronic asthma in adults – 2000 update. South African Pulmonology Society Adult Asthma Working Group. S Afr Med J 2000; 90(5 Pt 2):540-541.
  4. Lalloo UG, Ainslie G, Wong M, et al. Guidelines for the management of chronic asthma in adolescents and adults. S Afr Fam Pract 2007;49:19-31.
  5. Lalloo UG, Ainslie GM, Abdool-Gaffar MS, et al. Guideline for the management of acute asthma in adults: 2013 update. S Afr Med J 2012;103(3):189-198.
  6. South African Government. Government Gazette 25 February 2005. Compensation for Occupational Injuries and Disease Act (130/1993): Circular instruction regarding compensation for work-related asthma 2005. https://www.gov.za/sites/default/files/gcis_document/201409/273290.pdf (accessed 20 August 2021).
  7. GINA-GOLD. Diagnosis of Diseases of Chronic Airflow Limitation: Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS). http://www.goldcopd.org/asthmacopd-overlap.html (accessed 20 August 2021).
  8. Parsons JP, Hallstrand TS, Mastronarde JG, et al. An official American Thoracic Society clinical practice guideline: Exercise-induced bronchoconstriction. Am J Respir Crit Care Med 2013;187(9):1016-1027.
  9. Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: A systematic review and meta-analysis. Lancet Respir Med 2015;3(4):290-300.
  10. Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson M, Jhingran P. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol 2009;124(4):719-23.
  11. National Asthma Education Programme South Africa. Asthma Guide for patients 2021. http://www.asthmasa.org/asthma_guide.html (accessed 19 August 2021).
  12. Global Initiative for Asthma. You can control your asthma. 2021. https://ginasthma.org/gina-patient-guide-you-can-control-your-asthma/ (accessed 19 August 2021).
  13. Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B. Adverse respiratory effect of acute beta-blocker exposure in asthma: A systematic review and meta-analysis of randomized controlled trials. Chest 2014;145(4):779-786.
  14. Reddel HK, Busse WW, Pedersen S, et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: A post-hoc efficacy analysis of the START study. Lancet 2017;389(10065):157-166.
  15. O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide–formoterol as needed in mild asthma. N Engl J Med 2018;378(20):1865-1876.
  16. Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med 2019;380(21):2020-2030.
  17. Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2013;(9):CD000052. https://doi.org/10.1002%2F14651858.CD000052.pub3
  18. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343(5):332-336.
  19. Stanford RH, Shah MB, D’Souza AO, Dhamane AD, Schatz M. Short-acting beta-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol 2012;109(6):403-407.
  20. Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: A nationwide cohort study of the global SABINA programme. Eur Respir J 2020;55(4):1901872.
  21. Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev 2013;(4):CD007313.
  22. Van Zyl-Smit RN, Krull M, Gessner C, et al. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): A randomised, double-blind, tripledummy, controlled phase 3 study. Lancet Respir Med 2020;8(10):987-999.
  23. Woodcock A, Bakerly ND, New JP, et al. The Salford Lung Study protocol: A pragmatic, randomised phase III real-world effectiveness trial in asthma. BMC Pulm Med 2015;15:160.
  24. Abdool-Gaffar MS, Calligaro G, Wong ML, et al. Management of chronic obstructive pulmonary disease – a position statement of the South African Thoracic Society: 2019 update. J Thorac Disease 2019;11(11):4408-4427.
  25. Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): A randomised, double-blind, controlled phase 3 study. Lancet Respir Med 2020;8(10):1000-1012.
  26. Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): A double-blind, randomised, phase 3A trial. Lancet Respir Med 2020;9(1):69-84.
  27. Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extra-fine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): Two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet 2019;394(10210):1737-1749.
  28. Chong JK, Chauhan BF. Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma. Paediatr Child Health 2014;19(9):473-474.
  29. US Food and Drug Administration. FDA requires boxed warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. 2020. https://www.fda.gov/drugs/drug-safety-andavailability/fda-requires-boxed-warning-about-serious-mental-health-side-effectsasthma-and-allergy-drug (accessed 27 September 2021).
  30. Dahl R, Larsen BB, Venge P. Effect of long-term treatment with inhaled budesonide or theophylline on lung function, airway reactivity and asthma symptoms. Respir Med 2002;96(6):432-438.
  31. Tee AK, Koh MS, Gibson PG, Lasserson TJ, Wilson AJ, Irving LB. Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev 2007;(3):CD001281.
  32. Hiles SA, McDonald VM, Guilhermino M, Brusselle GG, Gibson PG. Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis. Eur Respir J 2019;54(5):1901381. https://doi.org//10.1183/13993003.01381-2019
  33. Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet 2017;390(10095):659-668.
  34. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43(2):343-373.
  35. Woodruff PG, Modrek B, Choy DF, et al. T-helper Type 2–driven inflammation defines major subphenotypes of asthma. Am J Resp Crit Care Med 2009;180(5):388-395.
  36. Agache I, Akdis C, Jutel M, Virchow JC. Untangling asthma phenotypes and endotypes. Allergy 2012;67(7):835-846.
  37. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108(2):184-190.
  38. Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J Allergy Clin Immunol 2020;145(2):528-536.
  39. Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 2020;146(3):595-605.
  40. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371(13):1198-1207. https://doi.org/ 10.1056/NEJMoa1403290
  41. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016;388(10056):2115-2127.
  42. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;388(10056):2128-2141.
  43. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018;378:2486-2496.
  44. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018;378(26):2475-2485.
  45. Castro M, Musani AI, Mayse ML, Shargill NS. Bronchial thermoplasty: A novel technique in the treatment of severe asthma. Ther Adv Respir Dis 2010;4(2):101-116.
  46. Dheda K, Koegelenberg CF, Esmail A, et al. Recommendations for the use of bronchial thermoplasty in the management of severe asthma. S Afr Med J 2015;105(9):726-732.
  47. Murphy VE, Gibson PG. Asthma in pregnancy. Clin Chest Med 2011;32(1):93-110.
  48. Lazarinis N, Jorgensen L, Ekstrom T, et al. Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax 2014;69(2):130-136.
  49. Cormier M, Lemiere C. Occupational asthma. Int J Tuberc Lung Dis 2020;24(1):8-21.
  50. Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol 2015;135(4):896-902.
  51. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43(2): 343-373.

Guidelines for the management of asthma in adults and adolescents, South African Thoracic Society, 2021

Drugs mentioned

NeoHealth® ID 24518 · updated 5/5/2022